Loading...
•
Sep 30, 2020
Rigel Q3 2020 Earnings Report
Reported financial results for the third quarter ended September 30, 2020.
Key Takeaways
Rigel Pharmaceuticals reported third quarter total revenues of $18.4 million, including net product sales of $16.3 million, a 39% year-over-year increase. The company's net loss was $14.2 million, or $0.08 per share.
Total revenues were $18.4 million.
Net product sales were $16.3 million, a 39% year-over-year increase.
Launched Phase 3 clinical trial of fostamatinib in COVID-19 patients.
Net loss of $14.2 million, or $0.08 per share.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...